Risk of Gastrointestinal Bleeding with Rivaroxaban: A Comparative Study with Warfarin
Introduction. The risk of gastrointestinal (GI) bleeding with rivaroxaban has not been studied extensively. The aim of our study was to assess this risk in comparison to warfarin. Methods. We examined the medical records for patients who were started on rivaroxaban or warfarin from April 2011 to Apr...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2016-01-01
|
| Series: | Gastroenterology Research and Practice |
| Online Access: | http://dx.doi.org/10.1155/2016/9589036 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832564955540357120 |
|---|---|
| author | Muhammed Sherid Samian Sulaiman Salih Samo Husein Husein Ruth Tupper Charles Spurr Humberto Sifuentes Subbaramiah Sridhar |
| author_facet | Muhammed Sherid Samian Sulaiman Salih Samo Husein Husein Ruth Tupper Charles Spurr Humberto Sifuentes Subbaramiah Sridhar |
| author_sort | Muhammed Sherid |
| collection | DOAJ |
| description | Introduction. The risk of gastrointestinal (GI) bleeding with rivaroxaban has not been studied extensively. The aim of our study was to assess this risk in comparison to warfarin. Methods. We examined the medical records for patients who were started on rivaroxaban or warfarin from April 2011 to April 2013. Results. We identified 300 patients (147 on rivaroxaban versus 153 on warfarin). GI bleeding occurred in 4.8% patients with rivaroxaban when compared to 9.8% patients in warfarin group (p=0.094). GI bleeding occurred in 8% with therapeutic doses of rivaroxaban (>10 mg/d) compared to 9.8% with warfarin (p=0.65). Multivariate analysis showed that patients who were on rivaroxaban for ≤40 days had a higher incidence of GI bleeding than those who were on it for >40 days (OR = 2.8, p=0.023). Concomitant use of dual antiplatelet agents was associated with increased risk of GI bleeding in the rivaroxaban group (OR = 7.4, p=0.0378). Prior GI bleeding was also a risk factor for GI bleeding in rivaroxaban group (OR = 15.5). Conclusion. The incidence of GI bleeding was similar between rivaroxaban and warfarin. The risk factors for GI bleeding with rivaroxaban were the first 40 days of taking the drug, concomitant dual antiplatelet agents, and prior GI bleeding. |
| format | Article |
| id | doaj-art-54ad8ffe177a452288f8fc227838104e |
| institution | Kabale University |
| issn | 1687-6121 1687-630X |
| language | English |
| publishDate | 2016-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Gastroenterology Research and Practice |
| spelling | doaj-art-54ad8ffe177a452288f8fc227838104e2025-02-03T01:09:50ZengWileyGastroenterology Research and Practice1687-61211687-630X2016-01-01201610.1155/2016/95890369589036Risk of Gastrointestinal Bleeding with Rivaroxaban: A Comparative Study with WarfarinMuhammed Sherid0Samian Sulaiman1Salih Samo2Husein Husein3Ruth Tupper4Charles Spurr5Humberto Sifuentes6Subbaramiah Sridhar7Section of Gastroenterology and Hepatology, Georgia Regents University, 1120 15th Street, AD 2226, Augusta, GA 30912, USADepartment of Internal Medicine, Froedtert Hospital and Medical College of Wisconsin, 9200 West Wisconsin Avenue, Milwaukee, WI 53226, USADepartment of Medicine, Northwestern Memorial Hospital, Northwestern University Feinberg School of Medicine, 251 East Huron Street, Suite 16-738, Chicago, IL 60611, USADepartment of Internal Medicine, Seton Hall University, School of Health and Medicine Sciences, Trinitas Regional Medical Center, 225 Williamson Street, Elizabeth, NJ 07202, USADepartment of Internal Medicine, Saint Francis Hospital, 355 Ridge Avenue, Evanston, IL 60202, USASection of Gastroenterology and Hepatology, Georgia Regents University, 1120 15th Street, AD 2226, Augusta, GA 30912, USASection of Gastroenterology and Hepatology, Georgia Regents University, 1120 15th Street, AD 2226, Augusta, GA 30912, USASection of Gastroenterology and Hepatology, Georgia Regents University, 1120 15th Street, AD 2226, Augusta, GA 30912, USAIntroduction. The risk of gastrointestinal (GI) bleeding with rivaroxaban has not been studied extensively. The aim of our study was to assess this risk in comparison to warfarin. Methods. We examined the medical records for patients who were started on rivaroxaban or warfarin from April 2011 to April 2013. Results. We identified 300 patients (147 on rivaroxaban versus 153 on warfarin). GI bleeding occurred in 4.8% patients with rivaroxaban when compared to 9.8% patients in warfarin group (p=0.094). GI bleeding occurred in 8% with therapeutic doses of rivaroxaban (>10 mg/d) compared to 9.8% with warfarin (p=0.65). Multivariate analysis showed that patients who were on rivaroxaban for ≤40 days had a higher incidence of GI bleeding than those who were on it for >40 days (OR = 2.8, p=0.023). Concomitant use of dual antiplatelet agents was associated with increased risk of GI bleeding in the rivaroxaban group (OR = 7.4, p=0.0378). Prior GI bleeding was also a risk factor for GI bleeding in rivaroxaban group (OR = 15.5). Conclusion. The incidence of GI bleeding was similar between rivaroxaban and warfarin. The risk factors for GI bleeding with rivaroxaban were the first 40 days of taking the drug, concomitant dual antiplatelet agents, and prior GI bleeding.http://dx.doi.org/10.1155/2016/9589036 |
| spellingShingle | Muhammed Sherid Samian Sulaiman Salih Samo Husein Husein Ruth Tupper Charles Spurr Humberto Sifuentes Subbaramiah Sridhar Risk of Gastrointestinal Bleeding with Rivaroxaban: A Comparative Study with Warfarin Gastroenterology Research and Practice |
| title | Risk of Gastrointestinal Bleeding with Rivaroxaban: A Comparative Study with Warfarin |
| title_full | Risk of Gastrointestinal Bleeding with Rivaroxaban: A Comparative Study with Warfarin |
| title_fullStr | Risk of Gastrointestinal Bleeding with Rivaroxaban: A Comparative Study with Warfarin |
| title_full_unstemmed | Risk of Gastrointestinal Bleeding with Rivaroxaban: A Comparative Study with Warfarin |
| title_short | Risk of Gastrointestinal Bleeding with Rivaroxaban: A Comparative Study with Warfarin |
| title_sort | risk of gastrointestinal bleeding with rivaroxaban a comparative study with warfarin |
| url | http://dx.doi.org/10.1155/2016/9589036 |
| work_keys_str_mv | AT muhammedsherid riskofgastrointestinalbleedingwithrivaroxabanacomparativestudywithwarfarin AT samiansulaiman riskofgastrointestinalbleedingwithrivaroxabanacomparativestudywithwarfarin AT salihsamo riskofgastrointestinalbleedingwithrivaroxabanacomparativestudywithwarfarin AT huseinhusein riskofgastrointestinalbleedingwithrivaroxabanacomparativestudywithwarfarin AT ruthtupper riskofgastrointestinalbleedingwithrivaroxabanacomparativestudywithwarfarin AT charlesspurr riskofgastrointestinalbleedingwithrivaroxabanacomparativestudywithwarfarin AT humbertosifuentes riskofgastrointestinalbleedingwithrivaroxabanacomparativestudywithwarfarin AT subbaramiahsridhar riskofgastrointestinalbleedingwithrivaroxabanacomparativestudywithwarfarin |